<br>        Inclusion Criteria: • Presence of Rheumatoid Arthritis classified by ACR 2010 revised<br>        criteria for at least 3 months •Disease activity defined by =6 tender joints out of 68 and<br>        = 6 swollen joints out of 66 at baseline and with: Either Anti-CCP antibodies positive OR<br>        Rheumatoid Factor positive AND WITH Either hsCRP = 10 mg/L OR ESR =28 mm/1st hr •Intake of<br>        at least one anti-TNF-a agent such as etanercept, adalimumab, infliximab, certolizumab or<br>        golimumab for at least 3 months before entering the study and to have experienced an<br>        inadequate response to treatment or to have been intolerant to at least one administration<br>        Exclusion Criteria:<br><br>          -  Current RA functional status class IV according to the ACR 1991 revised criteria<br>             •Previous use of secukinumab or other biologic drug directly targeting IL-17 or IL-17<br>             receptor and/or any history of hypersensitivity to secukinumab or its excipient or to<br>             drugs of similar chemical classes. Other protocol-defined inclusion/exclusion criteria<br>             may apply<br>      ;<br>        Inclusion Criteria: • Presence of Rheumatoid Arthritis classified by ACR 2010 revised<br>        criteria for at least 3 months •Disease activity defined by =6 tender joints out of 68 and<br>        = 6 swollen joints out of 66 at baseline and with: Either Anti-CCP antibodies positive OR<br>        Rheumatoid Factor positive AND WITH Either hsCRP = 10 mg/L OR ESR =28 mm/1st hr •Intake of<br>        at least one anti-TNF-a agent such as etanercept, adalimumab, infliximab, certolizumab or<br>        golimumab for at least 3 months before entering the study and to have experienced an<br>        inadequate response to treatment or to have been intolerant to at least one administration<br>        Exclusion Criteria:<br><br>          -  Current RA functional status class IV according to the ACR 1991 revised criteria<br>             •Previous use of secukinumab or other biologic drug directly targeting IL-17 or IL-17<br>             receptor and/or any history of hypersensitivity to secukinumab or its excipient or to<br>             drugs of similar chemical classes. Other protocol-defined inclusion/exclusion criteria<br>             may apply<br>      ;<br>        Inclusion Criteria: • Presence of Rheumatoid Arthritis classified by ACR 2010 revised<br>        criteria for at least 3 months •Disease activity defined by =6 tender joints out of 68 and<br>        = 6 swollen joints out of 66 at baseline and with: Either Anti-CCP antibodies positive OR<br>        Rheumatoid Factor positive AND WITH Either hsCRP = 10 mg/L OR ESR =28 mm/1st hr •Intake of<br>        at least one anti-TNF-a agent such as etanercept, adalimumab, infliximab, certolizumab or<br>        golimumab for at least 3 months before entering the study and to have experienced an<br>        inadequate response to treatment or to have been intolerant to at least one administration<br>        Exclusion Criteria:<br><br>          -  Current RA functional status class IV according to the ACR 1991 revised criteria<br>             •Previous use of secukinumab or other biologic drug directly targeting IL-17 or IL-17<br>             receptor and/or any history of hypersensitivity to secukinumab or its excipient or to<br>             drugs of similar chemical classes. Other protocol-defined inclusion/exclusion criteria<br>             may apply<br>      ;<br>        Inclusion Criteria: • Presence of Rheumatoid Arthritis classified by ACR 2010 revised<br>        criteria for at least 3 months •Disease activity defined by =6 tender joints out of 68 and<br>        = 6 swollen joints out of 66 at baseline and with: Either Anti-CCP antibodies positive OR<br>        Rheumatoid Factor positive AND WITH Either hsCRP = 10 mg/L OR ESR =28 mm/1st hr •Intake of<br>        at least one anti-TNF-a agent such as etanercept, adalimumab, infliximab, certolizumab or<br>        golimumab for at least 3 months before entering the study and to have experienced an<br>        inadequate response to treatment or to have been intolerant to at least one administration<br>        Exclusion Criteria:<br><br>          -  Current RA functional status class IV according to the ACR 1991 revised criteria<br>             •Previous use of secukinumab or other biologic drug directly targeting IL-17 or IL-17<br>             receptor and/or any history of hypersensitivity to secukinumab or its excipient or to<br>             drugs of similar chemical classes. Other protocol-defined inclusion/exclusion criteria<br>             may apply<br>